Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
USRE42353 | GENZYME CORP | Quinazoline derivatives and pharmaceutical compositions containing them |
Jun, 2022
(7 months ago) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8642608 | GENZYME CORP | Quinazoline derivatives as VEGF inhibitors |
Feb, 2022
(1 year, 3 days ago) | |
US8067427 | GENZYME CORP | Pharmaceutical compositions comprising ZD6474 |
Aug, 2028
(5 years from now) |
Market Authorisation Date: 06 April, 2011
Treatment: For use in patients having symptomatic or progressive medullary thyroid cancer, with unresectable locally advanced or metastatic disease
Dosage: TABLET;ORAL
10
United States
5
European Union
4
Korea, Republic of
3
Austria
3
Hong Kong
3
Brazil
3
Spain
3
Germany
3
Slovenia
3
United Kingdom
3
Argentina
3
Portugal
3
China
3
Norway
3
Denmark
2
Australia
2
Poland
2
Ukraine
2
Israel
2
Cyprus
2
Mexico
2
Japan
2
South Africa
2
Russia
2
ME
2
Iceland
2
Canada
2
New Zealand
2
Taiwan, Province of China
1
Estonia
1
RS
1
Malaysia
1
Saudi Arabia
1
Luxembourg
1
Slovakia
1
Uruguay
1
Hungary
1
Belgium
1
Bulgaria
1
Croatia
1
Czech Republic
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic